
3
Working versus Retiring
The era of steady employment after 
school or college, working until 
retirement age and living out a dotage 
is becoming less common. People 
with HIV infection, especially those 
diagnosed prior to the era of highly active 
antiretroviral therapy (HAART), have 
often worked only sporadically or have 
retired early. Now that life expectancy has 
increased, many are considering second 
careers, going back to train or working 
either full or part-time. Apart from the 
obvious financial rewards, this can bring 
physical, mental and social benefits. 
There is robust evidence that ongoing 
mental and physical activity throughout 
life has a significant impact in prolonging 
both quantity and quality of life. It is 
nonetheless important to establish 
a balance to ensure that continued 
employment is not physically and 
mentally stressful, and therefore 
detrimental to health. Equally it is 
important that retirement does not lead 
to reduction in physical, mental and 
social stimulation or isolation. Therefore 
to a certain extent, each individual can 
influence this process by what they do 
and how they choose to live. Advanced 
planning should include recognition and 
acceptance of individual risks and regular 
review of how personal lifestyle can be 
improved. It is not possible to predict 
the future but it is possible to plan for a 
healthier old age. Research indicates that 
only a proportion of longevity (length 
of life) is genetically determined whilst 
the bulk of it depends on lifestyle and 
environmental factors (external factors 
such as infections, sunlight or accidents, 
for example). 
Section 3: Le Patient   21
Qui doit être testé? ....................................................21
1. Dépistage HVB  ..........................................................21
2. Dépistage HVC  ..........................................................24
Réduction des risques .................................................26
Partenaires et membres de la famille  ...................................26
Vaccination HVB  ......................................................26
Section 4: Evaluation   28
Evaluation générale ...................................................28
Evaluation de l’infection au VHB ........................................31
Evaluation de l’infection au VHC ........................................31
Facteurs à considérer avant de commencer le traitement
1. Maladies autoimmunes  .................................................31
2. Conditions concomitantes ...............................................32
3. Autres questions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32
Section 5: Traitement   35
Traitement de l’hépatite B  .............................................35
Traitement de l’hépatite C  .............................................35
Recommandations pour la surveillance et le traitement .................36
Section 6: Further Information and Appendices
Liens Web et ressources ................................................38
Annexes ..............................................................39
Annexe 1 - Feuille de rapport FibroScan® ...................................39
Annexe 2  - Echelle hospitalière de mesure de l’anxiété et de la dépression .39
Annexe 3 - Test rapide de détection d’alcool ...............................39
Remerciements  .......................................................40